140 related articles for article (PubMed ID: 19088161)
1. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.
Juul A; Sørensen K; Aksglaede L; Garn I; Rajpert-De Meyts E; Hullstein I; Hemmersbach P; Ottesen AM
J Clin Endocrinol Metab; 2009 Mar; 94(3):1005-11. PubMed ID: 19088161
[TBL] [Abstract][Full Text] [Related]
2. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation.
Schulze JJ; Lundmark J; Garle M; Skilving I; Ekström L; Rane A
J Clin Endocrinol Metab; 2008 Jul; 93(7):2500-6. PubMed ID: 18334593
[TBL] [Abstract][Full Text] [Related]
3. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse.
Okano M; Ueda T; Nishitani Y; Kano H; Ikekita A; Kageyama S
Drug Test Anal; 2013 Mar; 5(3):166-81. PubMed ID: 22887913
[TBL] [Abstract][Full Text] [Related]
4. Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys.
Mouritsen A; Busch AS; Aksglaede L; Rajpert-De Meyts E; Juul A
Endocr Connect; 2018 Mar; 7(3):460-465. PubMed ID: 29467232
[TBL] [Abstract][Full Text] [Related]
5. Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men.
Schulze JJ; Thörngren JO; Garle M; Ekström L; Rane A
J Clin Endocrinol Metab; 2011 Nov; 96(11):3440-7. PubMed ID: 21849521
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.
Anielski P; Simmchen J; Wassill L; Ganghofner D; Thieme D
Drug Test Anal; 2011 Oct; 3(10):645-51. PubMed ID: 21928278
[TBL] [Abstract][Full Text] [Related]
7. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
8. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests.
Schulze JJ; Lundmark J; Garle M; Ekström L; Sottas PE; Rane A
Steroids; 2009 Mar; 74(3):365-8. PubMed ID: 19056415
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism.
Strahm E; Mullen JE; Gårevik N; Ericsson M; Schulze JJ; Rane A; Ekström L
Drug Test Anal; 2015; 7(11-12):1063-70. PubMed ID: 26198073
[TBL] [Abstract][Full Text] [Related]
10. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.
Schulze JJ; Lorentzon M; Ohlsson C; Lundmark J; Roh HK; Rane A; Ekström L
Pharmacogenet Genomics; 2008 Jun; 18(6):477-85. PubMed ID: 18496127
[TBL] [Abstract][Full Text] [Related]
11. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.
Jakobsson J; Ekström L; Inotsume N; Garle M; Lorentzon M; Ohlsson C; Roh HK; Carlström K; Rane A
J Clin Endocrinol Metab; 2006 Feb; 91(2):687-93. PubMed ID: 16332934
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
[TBL] [Abstract][Full Text] [Related]
13. Impact of the UGT2B17 polymorphism on the steroid profile. Results of a crossover clinical trial in athletes submitted to testosterone administration.
Martín-Escudero P; Muñoz-Guerra JA; García-Tenorio SV; Garde ES; Soldevilla-Navarro AB; Galindo-Canales M; Prado N; Fuentes-Ferrer ME; Fernández-Pérez C
Steroids; 2019 Jan; 141():104-113. PubMed ID: 30503386
[TBL] [Abstract][Full Text] [Related]
14. Discordant genotyping results using DNA isolated from anti-doping control urine samples.
Choong E; Schulze JJ; Ericsson M; Rane A; Ekström L
Drug Test Anal; 2017 Jul; 9(7):994-1000. PubMed ID: 27706926
[TBL] [Abstract][Full Text] [Related]
15. The UGT2B17 gene deletion is not associated with prostate cancer risk.
Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
[TBL] [Abstract][Full Text] [Related]
16. Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes.
Ekström L; Cevenini L; Michelini E; Schulze J; Thörngren JO; Belanger A; Guillemette C; Garle M; Roda A; Rane A
Eur J Clin Invest; 2013 Mar; 43(3):248-55. PubMed ID: 23294483
[TBL] [Abstract][Full Text] [Related]
17. [Testosterone metabolism and doping test results].
Laczmański Ł; Medraś M
Endokrynol Pol; 2009; 60(1):58-62. PubMed ID: 19224506
[TBL] [Abstract][Full Text] [Related]
18. UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism.
Bang AK; Jørgensen N; Rajpert-De Meyts E; Juul A
Front Endocrinol (Lausanne); 2013; 4():94. PubMed ID: 23908645
[TBL] [Abstract][Full Text] [Related]
19. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population.
Che X; Yu D; Wu Z; Zhang J; Chen Y; Han Y; Wang C; Qi J
Clin Lab; 2015; 61(12):1905-10. PubMed ID: 26882814
[TBL] [Abstract][Full Text] [Related]
20. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation.
Sten T; Finel M; Ask B; Rane A; Ekström L
Steroids; 2009 Nov; 74(12):971-7. PubMed ID: 19643121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
